ResearchMoz

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

GBI Research
Published Date » 2011-11-22
No. Of Pages » 76

GBI Researchs report, Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD, provides an in-depth analysis of patient recruitment scenario for major indications under respiratory diseases. The report analyzes the number of clinical trials conducted for major indications. The report provides information about the total number of clinical trials conducted by phase, geography, major sponsors and the number of clinical trials conducted per year. Analysis of the total number of patients recruited for major indications is also carried out. The report analyzes the total number of patients recruited by phase of clinical trial, geography and major sponsors. Analysis of the average number of patients recruited per trial per year for various indications is also completed. 

Clinical trials are conducted to find novel therapies for respiratory diseases. The cost and time for conducting clinical trials for respiratory diseases is higher than other diseases. This is due to costly and time consuming testing methods. Patients are required to be tested for a longer duration leading to an increase in the total time required for drug effectiveness than seen in other diseases. Changing environmental conditions along with increases in tobacco smoking, air pollution and urbanization has lead to an increase in the prevalence of respiratory diseases. Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and Pulmonary Arterial Hypertension (PAH) are few of the major respiratory diseases for which an increased number of clinical trials are conducted in order to determine the most effective treatment. 

In accordance to World Health Organization (WHO), the most common chronic disease among children is asthma. Asthma affects nearly 235 million people in the world. COPD was the cause of 5% of the total deaths in 2005. Tobacco smoking is the leading cause of COPD and in 2030. COPD will be the third leading cause of death. In light if this it becomes more important to find remedies for chronic respiratory diseases. CF is one of the most prevalent life-shortening diseases. It is a genetic disease which affects multiple organs. 

It is important to recruit the right type and number of patients to check the efficacy and efficiency of drugs. Efficient patient recruitment leads to a decrease in the time and cost associated with patient recruitment. At present, the rate of new drug approvals is declining with every passing year. Pharmaceutical companies are under intense pressure to reduce the time required for drug development. There are many barriers to participation for the patients as well as the investigators who enroll patients into the trials. Advances in the diagnosis and treatment of respiratory diseases are leading to a greater interest of pharmaceutical companies in sponsoring research into respiratory diseases.

Scope

  • Insight on Clinical Trials conducted for major indications of respiratory diseases such as asthma, COPD, CF, PAH or Pulmonary Hypertension (PH) for the period 20002010.
  • The status of patient recruitment by geographical region, sponsor company, year and stage of development.
  • Analysis on the average number of patients recruited per trial for major indications per year.
  • Analysis on the average number of patients recruited per trial for major indications by stage of development.
  • The prevalence population in India, China and Brazil for all major indications from 2010-2017.

Reasons to buy

  • Identify and understand the status of clinical trials conducted for major respiratory indications from 2000-2010.
  • Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
  • Identify the prevalence population for the major indications till 2017.
  • Identify the average number of patients recruited by stage of development and across years for all major indications.
  • Identify the indication in which the maximum number of trials is conducted and and to which the maximum number of patients are recruited.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7

2 Clinical Trial Recruitment in Respiratlory Diseases - Introduction 9
2.1 Introduction 9
2.2 GBI Research Report Guidance 9

3 Clinical Trial Recruitment in Respiratory Diseases - Overview 11
3.1 Clinical Trials Share by Therapeutic Area, 2005-2010 11
3.2 Clinical Trials by Major Pharmaceutical Companies, 2005-2010 18

4 Clinical Trials and Patient Recruitment for Asthma 19
4.1 Introduction 19
4.2 Number of Clinical Trials for Asthma 20
4.2.1 Number of Clinical Trials by Phase 20
4.2.2 Number of Clinical Trials for Asthma by Major Sponsors 21
4.2.3 Number of Clinical Trials for Asthma by Geography 22
4.2.4 Number of Clinical Trials for Asthma by Year 23
4.3 Prevalence Population for Asthma (2010-2017) 24
4.3.1 India 24
4.3.2 China 25
4.3.3 Brazil 26
4.4 Patient Recruitment for Asthma 27
4.4.1 Number of Patients Recruited by Phase of Clinical Trials 27
4.4.2 Number of Patients Recruited by Major Sponsors 28
4.4.3 Number of Patients Recruited by Geography 29
4.4.4 Number of Patients Recruited per Year 30
4.5 Average Number of Patients Recruited Per Trial 31
4.5.1 Average Number of Patients Recruited per Trial by Stage of Development 31
4.5.2 Average Number of Patients Recruited per Trial per Year 32

5 Clinical Trials and Patient Recruitment for COPD 33
5.1 Introduction 33
5.2 Number of Clinical Trials for COPD 34
5.2.1 Number of Clinical Trials by Phase 34
5.2.2 Number of Clinical Trials by Sponsor 35
5.2.3 Number of Clinical Trials by Geography 36
5.2.4 Number of Clinical Trials by Year 37
5.3 Prevalence Population for COPD (2010-2017) 38
5.3.1 India 38
5.3.2 China 39
5.3.3 Brazil 40
5.4 Patient Recruitment for COPD 41
5.4.1 Number of Patients Recruited By Phase of Clinical Trial 41
5.4.2 Number of Patients Recruited By Sponsor 42
5.4.3 Number of Patients Recruited By Geography 43
5.4.4 Number of Patients Recruited per Year 44
5.5 Average Number of Patients Recruited Per Trial 45
5.5.1 Average Number of Patients Recruited per Trial by Stage of Development 45
5.5.2 Average Number of Patients Recruited per Trial per Year 46

6 Clinical Trials and Patient Recruitment for Cystic Fibrosis (CF) 47
6.1 Introduction 47
6.2 Number of Clinical Trials for CF 48
6.2.1 Number of Clinical Trials by Phase 48
6.2.2 Number of Clinical Trials by Major Sponsor 49
6.2.3 Number of Clinical Trials by Geography 50
6.2.4 Number of Clinical Trials by Year 51
6.3 Patient Recruitment for CF 52
6.3.1 Number of Patients Recruited By Phase of Clinical Trial 52
6.3.2 Number of Patients Recruited by Major Sponsors 53
6.3.3 Number of Patients Recruited by Geography 54
6.3.4 Number of Patients Recruited per Year 55
6.4 Average Number of Patients Recruited Per Trial by Stage of Development 56
6.4.1 Average Number of Patients Recruited per Trial by Stage of Development 56
6.4.2 Average Number of Patients Recruited per Trial per Year 57

7 Clinical Trials and Patient Recruitment for Pulmonary Hypertension (PH)/ Pulmonary Arterial Hypertension (PAH) 58
7.1 Introduction 58
7.2 Number of Clinical Trials for PH 59
7.2.1 Number of Clinical Trials by Phase 59
7.2.2 Number of Clinical Trials by Major Sponsors 60
7.2.3 Number of Clinical Trials by Geography 61
7.2.4 Number of Clinical Trials by Year 62
7.3 Prevalence Population for Pulmonary Hypertension (2010-2017) 63
7.3.1 India 63
7.3.2 China 64
7.3.3 Brazil 65
7.4 Patient Recruitment for PH 66
7.4.1 Number of Patients Recruited By Phase of Clinical Trial 66
7.4.2 Number of Patients Recruited by Major Sponsors 67
7.4.3 Number of Patients Recruited By Geography 68
7.4.4 Number of Patients Recruited Per Year 69
7.5 Average Number of Patients Recruited Per Trial by Stage of Development 70
7.5.1 Average Number of Patients Recruited per Trial by Stage of Development 70
7.5.2 Average Number of Patients Recruited per Trial per Year 71

8 Appendix 72
8.1 Market Definitions 72
8.2 Abbreviations 72
8.3 Research Methodology 73
8.3.1 Clinical Trials Overview 73
8.3.2 Number of Clinical Trials 73
8.3.3 Patient Recruitment Status 74
8.3.4 Prevalence of Disease in India, China and Brazil (2010-2017) 74
8.3.5 Coverage 74
8.3.6 Secondary Research 74
8.3.7 Primary Research 75
8.3.8 Expert Panel Validation 75
8.4 Contact Us 75
8.5 Disclaimer 75
8.6 Sources 76

List of Tables


Table 1: Clinical Trial Recruitment in Respiratory Diseases, Global, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 11
Table 2: Clinical Trial Recruitment in Respiratory Diseases, Asia, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 12
Table 3: Clinical Trial Recruitment in Respiratory Diseases, Europe, Number of Ongoing Trials by Therapeutic Area, 2005-2010 13
Table 4: Clinical Trial Recruitment in Respiratory Diseases, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010 14
Table 5: Clinical Trial Recruitment in Respiratory Diseases, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010 15
Table 6: Clinical Trial Recruitment in Respiratory Diseases, North America, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 16
Table 7: Clinical Trial Recruitment in Respiratory Diseases, Rest of the World, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 17
Table 8: Clinical Trial Recruitment in Respiratory Diseases, Global, Number of Clinical Trials by Major Pharmaceutical Companies, 2005-2010 18
Table 9: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Phase, 2000-2010 20
Table 10: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Major Sponsors, 2000-2010 21
Table 11: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Geography, 2000-2010 22
Table 12: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials per Year, 2000-2010 23
Table 13: Clinical Trial Recruitment in Respiratory Diseases, Asthma, India, Prevalence Population, million, 2010-2017 24
Table 14: Clinical Trial Recruitment in Respiratory Diseases, Asthma, China, Prevalence Population, million 2010-2017 25
Table 15: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Brazil, Prevalence Population, million 2010-2017 26
Table 16: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Phase, 2000-2010 27
Table 17: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Major Sponsors, 2000-2010 28
Table 18: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Geography, 2000-2010 29
Table 19: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited per Year, 2000-2010 30
Table 20: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 31
Table 21: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Average Number of Patients Recruited per Trial per Year, 2000-2010 32
Table 22: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials, 2000-2010 35
Table 23: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials by Major Sponsors, 2000-2010 35
Table 24: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials by Geography, 2000-2010 36
Table 25: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials per Year, 2000-2010 37
Table 26: Clinical Trial Recruitment in Respiratory Diseases, COPD, India, Prevalence Population, million, 2010-2017 38
Table 27: Clinical Trial Recruitment in Respiratory Diseases, COPD, China, Prevalence Population, million, 2010-2017 39
Table 28: Clinical Trial Recruitment in Respiratory Diseases, COPD, Brazil, Prevalence Population, million, 2010-2017 40
Table 29: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials per Year, 2000-2010 41
Table 30: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited by Major Sponsors, 2000-2010 42
Table 31: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited by Geography, 2000-2010 43
Table 32: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited per Year, 2000-2010 44
Table 33: Clinical Trial Recruitment in Respiratory Diseases, COPD, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 45
Table 34: Clinical Trial Recruitment in Respiratory Diseases, COPD, Average Number of Patients Recruited per Trial per Year, 2000-2010 46
Table 35: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Phase, 2000-2010 48
Table 36: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Major Sponsors, 2000-2010 49
Table 37: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Geography, 2000-2010 50
Table 38: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials per Year, 2000-2010 51
Table 39: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Phase, 2000-2010 52
Table 40: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Major Sponsors, 2000-2010 53
Table 41: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Geography, 2000-2010 54
Table 42: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited per Year, 2000-2010 55
Table 43: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 56
Table 44: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Average Number of Patients Recruited per Trial per Year, 2000-2010 57
Table 45: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Phase, 2000-2010 59
Table 46: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Major Sponsors, 2000-2010 60
Table 47: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Geography, 2000-2010 61
Table 48: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials per Year, 2000-2010 62
Table 49: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, India, Prevalence Population, 2010-2017 63
Table 50: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, China, Prevalence Population, 2010-2017 64
Table 51: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Brazil, Prevalence Population, 2010-2017 65
Table 52: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Phase, 2000-2010 66
Table 53: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Major Sponsors, 2000-2010 67
Table 54: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Geography, 2000-2010 68
Table 55: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited per Year, 2000-2010 69
Table 56: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 70
Table 57: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Average Number of Patients Recruited per Trial per Year, 2000-2010 71

List of Figures


Figure 1: Clinical Trial Recruitment in Respiratory Diseases, Global, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 11
Figure 2: Clinical Trial Recruitment in Respiratory Diseases, Asia, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 12
Figure 3: Clinical Trial Recruitment in Respiratory Diseases, Europe, Number of Ongoing Trials by Therapeutic Area, 2005-2010 13
Figure 4: Clinical Trial Recruitment in Respiratory Diseases, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010 14
Figure 5: Clinical Trial Recruitment in Respiratory Diseases, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010 15
Figure 6: Clinical Trial Recruitment in Respiratory Diseases, North America, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 16
Figure 7: Clinical Trial Recruitment in Respiratory Diseases, Rest of World, Ongoing Trials by Therapeutic Area, thousands, 2005-2010 17
Figure 8: Clinical Trial Recruitment in Respiratory Diseases, Global, Number of Clinical Trials by Major Pharmaceutical Companies, 2005-2010 18
Figure 9: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Phase, 2000-2010 20
Figure 10: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Major Sponsors, 2000-2010 21
Figure 11: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials by Geography, 2000-2010 22
Figure 12: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Clinical Trials per Year, 2000-2010 23
Figure 13: Clinical Trial Recruitment in Respiratory Diseases, Asthma, India, Prevalence Population, million, 2010-2017 24
Figure 14: Clinical Trial Recruitment in Respiratory Diseases, Asthma, China, Prevalence Population, million, 2010-2017 25
Figure 15: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Brazil, Prevalence Population, million 2010-2017 26
Figure 16: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Phase, 2000-2010 27
Figure 17: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Major Sponsors, 2000-2010 28
Figure 18: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited by Geography, 2000-2010 29
Figure 19: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Total Number of Patients Recruited per Year, 2000-2010 30
Figure 20: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 31
Figure 21: Clinical Trial Recruitment in Respiratory Diseases, Asthma, Average Number of Patients Recruited per Trial per Year, 2000-2010 32
Figure 22: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials, 2000-2010 34
Figure 23: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials by Major Sponsors, 2000-2010 35
Figure 24: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials by Geography, 2000-2010 36
Figure 25: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Clinical Trials per Year, 2000-2010 37
Figure 26: Clinical Trial Recruitment in Respiratory Diseases, COPD, India, Prevalence Population, million, 2010-2017 38
Figure 27: Clinical Trial Recruitment in Respiratory Diseases, COPD, China, Prevalence Population, million, 2010-2017 39
Figure 28: Clinical Trial Recruitment in Respiratory Diseases, COPD, Brazil, Prevalence Population, million, 2010-2017 40
Figure 29: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited by Phase, 2000-2010 41
Figure 30: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited by Major Sponsors, 2000-2010 42
Figure 31: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited by Geography, 2000-2010 43
Figure 32: Clinical Trial Recruitment in Respiratory Diseases, COPD, Total Number of Patients Recruited per Year, 2000-2010 44
Figure 33: Clinical Trial Recruitment in Respiratory Diseases, COPD, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 45
Figure 34: Clinical Trial Recruitment in Respiratory Diseases, COPD, Average Number of Patients Recruited per Trial per Year, 2000-2010 46
Figure 35: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Phase, 2000-2010 48
Figure 36: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Major Sponsors, 2000-2010 49
Figure 37: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials by Geography, 2000-2010 50
Figure 38: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Clinical Trials per Year, 2000-2010 51
Figure 39: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Phase, 2000-2010 52
Figure 40: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Major Sponsors, 2000-2010 53
Figure 41: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited by Geography, 2000-2010 54
Figure 42: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Total Number of Patients Recruited per Year, 2000-2010 55
Figure 43: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 56
Figure 44: Clinical Trial Recruitment in Respiratory Diseases, Cystic Fibrosis, Average Number of Patients Recruited per Trial per Year, 2000-2010 57
Figure 45: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Phase, 2000-2010 59
Figure 46: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Major Sponsors, 2000-2010 60
Figure 47: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials by Geography (%), 2000-2010 61
Figure 48: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Clinical Trials per Year, 2000-2010 62
Figure 49: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, India, Prevalence Population, 2010-2017 63
Figure 50: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, China, Prevalence Population, 2010-2017 64
Figure 51: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Brazil, Prevalence Population, 2010-2017 65
Figure 52: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Phase, 2000-2010 66
Figure 53: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Major Sponsors, 2000-2010 67
Figure 54: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited by Geography (%), 2000-2010 68
Figure 55: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Total Number of Patients Recruited per Year, 2000-2010 69
Figure 56: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2010 70
Figure 57: Clinical Trial Recruitment in Respiratory Diseases, Pulmonary Hypertension, Average Number of Patients Recruited per Trial per Year, 2000-2010 71

Upcoming Reports:

Personal Hygiene Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The personal hygiene market is growing significantly owing to the increasing interest of people for personal care and health concerns. Many new manufacturers are making their way into the market as a result of the rising trend of personal care products in growing economies.  Personal hygiene is the first step toward good grooming and better health. There are a variety of illnesses that can be prevented just by improving personal hygiene. Some illnesses are not a result of poor personal hygiene, but improving the standards of hygiene will control adverse conditions. ...
Pipeline Review Of Tuberculosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Globally, tuberculosis is a major cause of morbidity and mortality.Tuberculosis, is an infectious bacterial disease caused by Mycobacterium tuberculosis. It most commonly affects the lungs, although it can affect organs in the central nervous system, lymphatic system and circulatory system among others. It is transmitted from person to person via droplets from the lungs and throat of people with the active respiratory disease. The symptoms of active lung tuberculosis are coughing, sometimes with sputum or blood, chest pains, weakness, weight loss, fever and night sweats. Tuberculosis is...
LED Display Driver And Lighting IC Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
An LED display driver is an IC (integrated circuit) offers the circuitry essential in order to interface common microprocessors or digital systems to LED display. Included on an LED display driver may be a multiplex scan circuitry, static display memory and high current segment and digit drivers for displays. Among these two applications, LED Display Driver and IC Market for the lighting applications are estimated to grow with a high CAGR during forecasted period. Display application holds for the largest share of overall LED driver IC market. This market research report analyses...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...